

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

September 08, 2005

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**FORM 8-K
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 2, 2005**

IntraBiotics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-29993

94-3200380

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

1009 Oak Hill Road, Suite 201

Lafayette, CA 94549

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(925) 906-5331**

Not Applicable

(Former name or former address, if changed since last
report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On September 8, 2005, IntraBiotics Pharmaceuticals, Inc. (the Company) issued a press release announcing that it had received a letter dated September 2, 2005 from the staff of The NASDAQ Stock Market (the Staff) stating that the Staff believes the Company is a public shell and is therefore subject to delisting from NASDAQ on September 13, 2005, pursuant to Marketplace Rule 4300, unless the Company appeals the Staff 's determination to a NASDAQ Listing Qualifications Panel (the Panel). The Company will appeal the Staff 's determination and request a hearing. There can be no assurance that the Panel will grant the Company 's request for continued listing. The Company 's securities will remain listed on NASDAQ until the issuance of the Panel 's written determination.

The Company 's press release dated September 8, 2005 related to these events is attached to this Current Report as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

- (c) Exhibits. The following documents are filed as exhibits to this report:
99.1 Press Release dated September 8, 2005.
-

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**INTRABIOTICS
PHARMACEUTICALS, INC.**

Date: September 8, 2005

/s/ DENIS HICKEY
Denis Hickey
Chief Executive Officer

Table of Contents

EXHIBIT INDEX

Exhibit Number	Document Description
99.1	Press Release dated September 8, 2005